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Introduction
Acetylcholine is a neurotransmitter in the nervous system but 
it serves also as a paracrine or autocrine factor in different 
cell types, where it is linked to functions like proliferation 
and cell differentiation [1-3]. mAChRs mediate a wide array 
of cellular responses to acetylcholine in the central nervous 
system (CNS) and in non-nervous tissues innervated by the 
parasymphatic nervous system [4,5]. Muscarinic receptors are 
involved in diverse actions, including inhibition of adenylate 
cyclase, breakdown of phosphoinositide, regulation of nitric 
oxide (NO) synthesis, change of Ca2+ levels and modulation 
of K channels [6-8]. Muscarinic cholinergic receptors can also 
induce cell proliferation, differentiation and transformation. 
These effects are cell type dependent and receptor subtype 
specific. Many cells express a mixture of muscarinic receptor 
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ABSTRACT
Objectives: Muscarinic acetylcholine receptors (mAChR) belong 
to a family of G protein coupled receptors (GPCRs). These 
mAChRs regulate several important physiological functions by 
activating a wide variety of cellular signaling pathways.  We have 
previously shown that muscarinic acetylcholine (M
2
, M3 and M4) 
receptors are expressed in K562 cells. In this study, we investigated 
the effect of muscarinic agonist, antagonists and different signaling 
pathway inhibitors on c-Fos and cyclin D
1
 transcripts, using reverse 
transcriptase polymerase chain reaction (RT-PCR) that allows 
changes of very rare transcripts to be monitored. 
Material and Methods: Total RNA was prepared from K562 
cells challenged with muscarinic agonist, antagonists and inhibitors. 
c-Fos and cyclin D
1
 expression were determined by RT-PCR.
Results: We showed that treatment with muscarinic agonist, 
antagonists and inhibitors leads to changes in  c-Fos and cyclin D
1
 
expression in K562 cells.
Conclusions: Our results suggest that muscarinic receptors 
regulate expression of c-Fos and cyclin D
1
 genes in K562 cells via 
different signaling pathways. 
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ÖZET
Amaç: Muskarinik asetilkolin reseptörleri (mAChR) G protein 
ile kenetli reseptör ailesinin üyesidirler. mAChR farklı sinyal ileti 
yolakları aracılığı ile bazı mühim f izyolojik fonksiyonları düzenler. 
K562 hücrelerinde M
2
, M3 ve M4 reseptörlerinin eksprese olduğunu 
önceki çalışmalarımızda gösterdik. Bu çalışmada muskarinik 
agonist, antagonist ve farklı sinyal ileti yolağı inhibitörlerinin c-Fos 
ve siklin D
1
 ekspresyonuna etkileri araştırılmıştır
Gereç ve Yöntem: Muskarinik reseptör agonist, antagonist 
ve sinyal yolağı inhibitörlerinin c-Fos ve siklin D
1
 ekspresyonuna 
etkileri ters transkriptaz polimeraz zincir tepkimesi (TT-PZT) 
kullanılarak analiz edilmiştir.
Bulgular: Muskarinik agonist, antagonistler ve sinyal yolağı 
inhibitörleri K562 hücrelerinde c-Fos ve siklin D
1
 transkriptlerinde 
değişime neden olmuştur. 
Sonuç: Sonuçlarımız K562 hücrelerinde muskarinik reseptör 
aracılı c-Fos ve siklin D
1
. mRNA ekspresyonlarının  farklı sinyal 
ileti yolları ile düzenlendiğini düşündürmektedir.
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transcripts [9]. Some studies indicate that only the M
1 
and M3 
receptor subtypes demonstrate growth modulation [10,11]. 
Different researchers have suggested that nonneuronal 
acetylcholine and cholinergic agonists alter cell growth and 
proliferation of lymphocytes [12]. Costa et al. demonstrated 
that acetylcholine released from T-lymphocytes acts via the 
M3 acetylcholine muscarinic receptor (mAChR) to trigger 
nuclear signaling and up-regulation of gene expression in T- 
and B-lymphocytes [9]. Activation of mAChRs and nicotinic 
acetylcholine receptors (nAChRs) on lymphocytes increases 
the intracellular Ca2+ concentration, stimulates c-Fos gene 
expression and NO synthesis [9]. Fuji et al. showed that 
stimulation of mACh receptors induces Ca2+ oscillations 
and up-regulates c-Fos gene expression in T- and B-cell 
lines [13]. mAChR activation alters Ca2+, c-Fos and c-jun 
mRNA and protein levels in the glial cell line 1321N1 [9-
14]. Stimulation of muscarinic receptors induces expression 
of c-Fos in different cell lines including astrocytoma cells, 
neuroblastoma cells [15-18]. Muscarinic receptor expression 
has been recently observed in human mononuclear cells 
(MNL) and in some leukemic cell lines [8, 19-21]. We have 
previously demonstrated the presence of M
2
, M3 and M4 
mAChRs and M3 subtype mediated NO signaling in K562 
chronic myelogenous leukemic cells [8]. We also showed that 
collagenase clostridium histolyticum (CCh)-treatment leads 
to changes in muscarinic M
2
, M3 and M4 receptor transcripts 
as well as M
2
 and M3 protein levels [3]
 and enhances  cyclic 
adenosine monophosphate  (cAMP) accumulation in these 
cells [21]. 
Cyclin D
1
 is an important regulator of G
1
 to S-phase 
transition and an important cofactor for diverse transcription 
factors in different cell types [22]. Different studies showed 
that cyclin D
1
 is a predominantly cytoplasmic protein in 
mammalian cancer cell lines [23]. The aim of this study 
was to examine muscarinic receptor mediated c-Fos and 
cyclin D
1
 gene expression in K562 cells and to investigate 
the intracellular signaling pathways that couple receptor 
stimulation to these genes. 
Materials and Methods
Carbamylcholine chloride (Carbachol), atropine, gallamine, 
tropicamide, 4-diphenyl-acetoxy-N-methyl-piperidine 
methiodide (4-DAMP) were from Sigma Chemical Co., St. 
Louis, MO, U.S.A.; RPMI 1640  were from Sigma Chemical 
Co., St. Louis, MO, USA.; 2-aminoethoxydiphenyl borate 
(2APB), MEK1/2 inhibitor (UO126) were from Merck, 
Germany. Wortmannin was from Santa Cruz, CA.
Cell culture
K562 cells (American Type Culture Collection, VA, USA) 
seeded at 1X106 cells/ml were maintained at 37°C in culture 
flasks in RPMI 1640 supplemented with 10% fetal calf serum, 
in a humidified atmosphere of 5% CO
2
 and 95% air, with 
one half of the medium being replaced every 3-4 days. The 
cells were counted on a hemocytometer after dilution with 
0.4% trypan blue. The experiments were performed in cell 
suspensions adjusted to reach a concentration of 1X105 cells/
ml. Cells were placed into medium with 10% serum added. 
The effects of muscarinic receptor  agonist and  antagonists 
were investigated on the levels of c-Fos and cyclin D
1 
expression in K562 cells. Cells were pre-treated for 30 min 
with antagonists followed by CCh (100 μM) stimulation for 
30 min. Cells grown on flask in serum-free medium were 
deprived of growth factors for 24 h before challenge with 
100 µM CCh or its vehicle for 30 min. Inhibitors 2APB; 
inhibitor of Ins(1,4,5)P3-induced Ca
2+ release from ER, 
Wortmannin; inhibitor of phoshoinositide 3-kinase, UO126; 
selective inhibitor of both MEK1 and MEK2) were added 30 
min prior to CCh. The cells were washed twice, resuspended 
in phosphate buffered saline (PBS) and centrifuged at 700 g 
for 5 min at room temperature.
RNA extraction: Total RNA was isolated by the 
guanidium thiocyanatephenol-chloroform extraction method, 
as previously described by Chomczynski and Sacchi [24]. 
Purity and quantitation  were assessed by A
260
/A
280
 ratios.
Reverse transcription: Reverse transcription of total 
RNA was carried out in a volume of 50 µl containing 0.2 
mM deoxynucleoside triphosphates, 1.5-3.0 mM MgCl
2
, 2-3 
µg RNA, 50 pmol of primers and 10 ml 5XRT-PCR buffer 
(Roche One step RT-PCR kit). The following primers were 
used to amplify cyclin D
1
(726bp), c-Fos (431bp) and b actin 
(660bp). Cyclin D
1
, upstream 5′- CCC TCG GTG TCC TAC 
TTC AAA -3′ and downstream 5′- CAC CTC CTC CTC CTC 
CTC TTC-3; c-Fos, upstream, 5- CCT  CAC CCT TTC GGA 
GTC CC-3′ and downstream 5′-  CTC CTT CAG CAG GTT 
GGC AAT CT -3′. b actin, upstream 5′ - GAC GGG GTC 
ACC CAC ACT GTG CCC ATC TA-3′ and downstream 
5′- CTA GAA GCA TTT GCG GTG GAC GAT GGA GG-
3′[19, 25-27]. Amplification was carried out for a total of 30 
cycles. After an initial denaturation step of 2 min at 94°C, 
amplification was carried out for a total of 30 cycles according 
to the following parameters: 94°C for 30 s, 55°C for 45 s, and 
72°C for 45 s, 30 cycles, 72°C for 4 min,1 cycle. As a negative 
control, the reverse transcriptase (RT) enzyme was omitted 
from the reaction mixture. Samples were electrophoresed on 
2% agarose gels, containing 1 μg/ml ethidium bromide and 
were viewed under UV light. Gels were photographed and 
analyzed on Biodoc Analyze software (Whatman Biometra). 
Data were presented as a sample experiment. The 
experiments were repeated twice (duplicated), yielding 
essentially identical results. Data were analyzed and graphics 
were drawn on GraphPad Prism 5 software. Data were 
presented as a percentage of the control.
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Results
1. The effect of carbachol treatment on cyclin D
1
 
expression in K562 cells
Muscarinic agonist CCh treatment decreased cyclin D
1
 
expression in K562 cells. Preincubation for 30 min with the 
muscarinic antagonists atropine, gallamine and tropicamide 
reversed CCh effects on cyclin D
1
 expression, in contrast to 
4-DAMP, which had no effect (Figure 1 A,B ).
2. The effect of carbachol treatment on c-Fos 
expression in K562 cells
Carbachol led to a small decrease in c-Fos mRNA levels. 
The decrease induced by CCh on c-Fos mRNA levels was 
prevented by the muscarinic antagonist, tropicamide (Figure 
2). 
3. Effect of CCh and inhibitors on cyclin D
1
 and c-Fos 
expression in K562 cells 
To investigate the role of signaling pathways in CCh-
mediated effects on cyclin D
1
 and c-Fos expression, we 
challenged K562 cells with the calcium chelator 2APB, 
Phosphoinositide (PI) 3-kinase inhibitor, wortmannin, and 
MEK 1-2 inhibitor UO126. The inhibitory effect of CCh on 
c-Fos expression was fully reversed by UO126, whereas the 
effect on cyclin D
1
 expression was potentiated by all three 
inhibitors (Figure 3 A,B). 
Discussion
Muscarinic receptors regulate multiple signaling pathways 
by activating G proteins. mAChR subtypes are widely 
expressed in the central and peripheral nervous systems [4, 
28]. Previous different studies postulated that muscarinic 
acetylcholine receptors are functional in some hematopoietic 
cells [8, 21-29]. Our previous RT-PCR studies have shown 
Figure 3 A, B. RT-PCR identified cDNA for Cyclin D
1
 and c-Fos in cultured 
K562 cells. K562 cells were treated with 100 µM CCh for 30 min. Inhibitors 
were added 30 min prior to CCh. Gene transcript quantity was measured by 
relative RT-PCR using the internal standard β-actin RT-PCR signal. PCR 
products of cyclin D
1
 and c-Fos were resolved on 2% agarose gels and 
visualized by ethidium bromide staining. A) Cyclin D
1
 and c-Fos expression. 
Data are presented as a sample experiment. Inhibitors: Marker (M), 
Control (Cont), CCh; (2APB+CCh), (UO126+CCh) (Wortmannin+CCh), 
M. B) mRNA levels were normalized to β-actin mRNA levels. Data were 
presented as a percentage of control. The experiments were repeated twice 
(duplicated). PCR products of the expected sizes were as follows: Cyclin D
1
 
(726bp), c-Fos (431bp) and b-actin (660bp).
Figure 1 A, B. RT-PCR identified cDNA for cyclin D
1 
mRNA levels in K562 
cells. A) K562 cells treated with 100 µM CCh for 30 min. Antagonists were 
added 30 min prior to CCh. Data are presented as a sample experiment. 1) 
Control, 2) CCh, 3) Atropine, 4) Gallamine, 5) Tropicamide, 6) 4DAMP, 
7) Control, 8) CCh, 9) (Atropine+CCh), 10) (Gallamine+CCh), 11) 
(Tropicamide+CCh), 12) (4DAMP+CCh). B) mRNA levels were normalized 
to β-actin mRNA levels. The experiments were repeated twice(duplicated), 
yielding essentially identical results. Data were presented as a percentage 
of control. PCR products of  the expected sizes were as follows: Cyclin D
1
 
(726bp), and b-actin (660bp).
Figure 2. RT-PCR identified cDNA for c-Fos mRNA levels in K562 cells. 
K562 cells were  treated with 100 µM CCh for 30 min. Antagonists were 
added 30 min prior to CCh. Gene transcript quantity was measured by relative 
RT-PCR 1) Control, 2) CCh, 3) (Atropine+CCh), 4)  (Gallamine+CCh), 5) 
(Tropicamide+CCh), 6) (4DAMP+CCh), 7) Marker (M). Data are presented 
as a sample experiment. β-actin was used as the loading control. The 
experiments were repeated twice (duplicated), yielding essentially identical 
results. PCR products of  the expected sizes were as follows: c-Fos (431bp) 
and b-actin (660bp).
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that M
2
, M3 and M4 mAChR subtypes are expressed in K562 
cells and suggested that they are involved in regulation of NO 
signaling and adenylate cyclase activity [8, 29]. This study 
was designed to test whether muscarinic agonist carbachol 
regulates cyclin D
1
 and c-Fos expression in K562 cells.
We found that exposure of K562 cells supplemented 
with 10% serum to CCh led to an inhibition of DNA 
synthesis [3] and a decrease in cyclin D
1
 expression. 
Inhibition of cyclin D
1
 expression was fully reversed by the 
muscarinic antagonists atropine (non-selective), gallamine 
(M
2
/M
4
 selective) and tropicamide (M
4
  selective) but not by 
4-DAMP (M3 selective). In order to explore the underlying 
intracellular signaling pathways involved in CCh-induced 
inhibition of cyclin D
1
, K562 cells were treated with pathway 
specific inhibitors. Neither the calcium chelator 2APB, PI3 
Kinase inhibitor, wortmannin, nor MEK 1-2 inhibitor UO126 
reversed the inhibiton. On the contrary, inhibition was 
enhanced with all of the inhibitors. In a previous study by 
Nicke et al. carbachol-induced inhibition of DNA synthesis 
was detected in 3T3 cells and this effect was found to be 
accompanied with an increase in p21cip1, a decrease in cyclin 
D
1
 and E levels, and Rb hypophosphorylation [30]. This study 
also showed that the time course of cyclin D
1
 degradation 
closely paralleled the observed inhibition of DNA synthesis. 
Stimulation of muscarinic receptors are known to induce 
c-Fos expression in neuronal cell lines and brain regions [15]. 
Trejo et al. suggested that the mobilization of intracellular 
Ca2+ and activation of protein kinase C within the first minute 
of mAChR occupation are sufficient for induction of c-Fos 
and c-jun in a glial cell line [29, 31]. Muscarinic receptors 
have been shown couple to both growth-stimulatory and 
inhibitory signaling pathways depending on the cell model 
and the assay conditions [30]. Under conditions of DNA 
inhibition, CCh led to a slight decrease in c-Fos expression in 
K562 cells. CCh-induced inhibition of c-Fos was abrogated 
by the M
4
 muscarinic antagonist, tropicamide. UO126 
reversed the inhibition induced by CCh, suggesting that the 
muscarinic receptor induced effect on c-Fos gene may be 
regulated via the MEK 1-2 pathway. 
In conclusion, our data imply that muscarinic receptors 
are involved in regulation of cyclin D
1
 and c-Fos expression 
through different muscarinic receptor subtypes and signal 
transduction pathways in K562 cells. 
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